District court patent filings are back down to roughly double the number of Patent Trial and Appeal Board (PTAB) filings, with 65 new complaints to the PTAB’s 28 new inter partes reviews (IPRs) and one post grant review (PGR). The complaints were driven by the Rothschild entities, adding defendants to existing campaigns, and a fair number of pharmaceutical complaints.
Recent Posts
- The PTAB’s 70% All-Claims Invalidation Rate Continues to Be a Source of Concern
- Novartis’ Entresto Patent Claims Revived by CAFC
- INTA Urges EUIPO Grand Board to Confirm Human Face Marks are Not Excluded from Trademark Registration
- New USPTO Fee Rule for Continuing Applications: Key Changes and Strategic Considerations for Applicants
- AI and the Level of Ordinary Skill: Why Patent Law Must (and Can) Adapt to AI-Augmented Invention